Biotech Earnings Roundup: Q1 2026 Results From Regeneron, Vertex, and Gilead

Three large-cap biotechs reported Q1 2026 results reflecting a broadly healthy sector quarter. Regeneron Pharmaceuticals (REGN) posted revenue of $3.6 billion, up 19% year over year. Vertex Pharmaceuticals (VRTX) reported $2.99 billion in total revenue, an 8% increase. Gilead Sciences (GILD) recorded total product sales of $6.9 billion, up 5%, with the base business excluding Veklury growing 8% to $6.8 billion. Each company is managing a transition from its current flagship franchise toward the next generation of products, absorbing upfront costs to fund that shift.

Regeneron: DUPIXENT's Scale and the EYLEA Transition

DUPIXENT global net sales reached $4.9 billion in Q1 2026, up 31% on a constant-currency basis. The drug is now treating over 1.4 million patients worldwide, placing it on an annualized run rate approaching $20 billion. Originally approved for atopic dermatitis, DUPIXENT has since expanded into asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis, among other indications. The breadth of approved uses continues to widen the addressable patient population.

The ophthalmology portfolio tells a more nuanced story. EYLEA HD U.S. sales were $468 million in Q1 2026, a 52% increase year over year, as the higher-dose formulation gains traction among retinal specialists. The original EYLEA declined 36% over the same period. The net effect is a portfolio in active transition: the newer product is growing fast enough to partially offset legacy volume erosion, though the full crossover point remains ahead.

A near-term regulatory event centers on a prefilled syringe application for EYLEA HD, with an FDA decision anticipated later this year. Approval would simplify administration and could support further uptake in the wet age-related macular degeneration and diabetic macular edema markets. The Regeneron Q1 2026 earnings breakdown at betafinch.com/podcasts/REGN_Q1_2026 covers these ophthalmology and DUPIXENT dynamics in full.

Vertex: Speed to Market and a New Renal Franchise

Vertex reported Q1 2026 non-GAAP earnings per share of $4.47 on total revenue of $2.99 billion. The cystic fibrosis portfolio remains the core, but two newer products, KASJEVY and GERNAVICS, collectively contributed approximately 25% of revenue growth in the quarter. That proportion signals that the company's revenue base is beginning to diversify beyond its foundational CF modulator franchise.

The more closely watched development was in renal disease. Povitacicept's Phase III interim results showed a 52% reduction in proteinuria in patients with IgA nephropathy. Proteinuria, the presence of excess protein in urine, is a key marker of kidney damage progression; a reduction of that magnitude in a Phase III setting is clinically meaningful. From database lock to regulatory submission, Vertex completed the filing in 27 days, which the company described as the fastest such turnaround in its history.

Vertex ended Q1 2026 with $13 billion in cash and investments, providing substantial capacity for pipeline investment or business development. The company also repurchased approximately $344 million in shares during the quarter. The full IgA nephropathy approval timeline and any additional interim data readouts from the Povitacicept program are the next milestones on the calendar for the renal franchise. The Vertex Pharmaceuticals Q1 2026 earnings breakdown at betafinch.com/podcasts/VRTX_Q1_2026 offers episode-length analysis of the CF and renal pipelines.

Gilead: HIV Dominance and a $11.5 Billion Acquisition Wave

Gilead's HIV franchise remained the primary growth engine in Q1 2026. Biktarvy generated $3.4 billion in sales for the quarter and held more than 52% of the U.S. HIV treatment market by share. At that penetration level, incremental share gains become structurally harder to achieve, and Gilead's strategy has shifted toward protecting the treatment base while layering in HIV prevention as the next growth vector.

Yes2Go, Gilead's long-acting HIV prevention therapy, recorded Q1 2026 sales of $166 million, a 72% jump from the prior quarter. Gilead raised its full-year HIV growth guidance to 8% and now expects Yes2Go to reach $1 billion in annual sales. The prevention market targets a broader, healthy population and depends on access, reimbursement decisions, and prescriber comfort with injectable regimens. Persistency data, which measures whether patients continue on therapy over time, will be a key indicator of how Yes2Go builds its patient base.

On the M&A front, Gilead closed three acquisitions, Arcellx, Tubulis, and Oral Medicines, for approximately $11.5 billion in upfront costs. The transactions are expected to produce a reported loss per share for 2026. Arcellx brings a CAR-T asset, anitocel, in late-stage development for multiple myeloma. Tubulis adds antibody-drug conjugate technology, and Oral Medicines expands the small-molecule pipeline. Together, the three deals represent a significant commitment to oncology and next-generation HIV as growth pillars beyond the current decade.

Milestones Ahead

Each company enters the second half of 2026 with a defined set of near-term milestones that will shape the narrative for the remainder of the year. The common thread across all three is that flagship products are funding the next generation of franchises, with near-term catalysts that will begin to quantify the returns on that investment.

• EYLEA HD prefilled syringe: FDA decision expected later in 2026; outcome affects Regeneron's ophthalmology portfolio trajectory as the EYLEA-to-EYLEA HD transition continues.
• Povitacicept full approval timeline: additional data and a regulatory clock following Vertex's record-speed 27-day database-lock-to-filing turnaround in IgA nephropathy.
• Yes2Go persistency data: early-adoption metrics that signal whether the drug can sustain its 72% quarter-over-quarter ramp toward $1 billion in annual sales.
• Arcellx anitocel readouts: late-stage data from Gilead's largest acquisition, with multiple myeloma as the initial CAR-T indication.

All three companies absorbed meaningful near-term costs, whether from R&D investment in new platforms, M&A charges, or the revenue drag of product transitions, in pursuit of franchises still in their build phase. The milestones above are where the return on that investment begins to become measurable.